Antiangiogenic therapies [302, 303] have been developed for well-established vascular targets including VEGF and its receptors [304, 305], suggesting the use of tumor vasculature specific and tumor-homing peptides to inhibit tumor-induced angiogenesis [302, 303]. The gene discussed is VEGFA; the disease is neoplasm.